NasdaqGS:UBX

Stock Analysis Report

Executive Summary

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span.

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Does not have meaningful revenue ($1M)



Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Unity Biotechnology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: UBX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.3%

UBX

0.2%

US Biotechs

0.6%

US Market


1 Year Return

-47.5%

UBX

17.8%

US Biotechs

20.8%

US Market

Return vs Industry: UBX underperformed the US Biotechs industry which returned 17.8% over the past year.

Return vs Market: UBX underperformed the US Market which returned 20.8% over the past year.


Shareholder returns

UBXIndustryMarket
7 Day16.3%0.2%0.6%
30 Day32.3%9.3%2.5%
90 Day5.0%15.9%4.9%
1 Year-47.5%-47.5%18.8%17.8%23.5%20.8%
3 Yearn/a27.1%22.9%46.5%37.0%
5 Yearn/a3.0%-2.1%64.6%46.5%

Price Volatility Vs. Market

How volatile is Unity Biotechnology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Unity Biotechnology undervalued compared to its fair value and its price relative to the market?

3.21x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate UBX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate UBX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: UBX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: UBX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate UBX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: UBX is good value based on its PB Ratio (3.2x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Unity Biotechnology forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-86.4%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if UBX's forecast earnings growth is above the savings rate (1.7%).

Earnings vs Market: Insufficient data to determine if UBX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: UBX is forecast to have no revenue next year.

High Growth Revenue: UBX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: UBX is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Unity Biotechnology performed over the past 5 years?

-28.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: UBX is currently unprofitable.

Growing Profit Margin: UBX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if UBX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare UBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: UBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).


Return on Equity

High ROE: UBX has a negative Return on Equity (-75.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Unity Biotechnology's financial position?


Financial Position Analysis

Short Term Liabilities: UBX's short term assets ($125.9M) exceed its short term liabilities ($14.3M).

Long Term Liabilities: UBX's short term assets ($125.9M) exceed its long term liabilities ($12.6M).


Debt to Equity History and Analysis

Debt Level: UBX is debt free.

Reducing Debt: UBX has not had any debt for past 5 years.


Balance Sheet

Inventory Level: UBX has a low level of unsold assets or inventory.

Debt Coverage by Assets: UBX's debt is not covered by short term assets (assets are -1463.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: UBX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: UBX has sufficient cash runway for 1.456792 years if free cash flow continues to reduce at historical rates of -36.9% each year.


Next Steps

Dividend

What is Unity Biotechnology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate UBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate UBX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if UBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if UBX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of UBX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Unity Biotechnology's salary, the management and board of directors tenure and is there insider trading?

3.9yrs

Average management tenure


CEO

Keith Leonard (57yo)

3.2yrs

Tenure

US$2,725,275

Compensation

Mr. Keith R. Leonard, Jr., M.S., M.B.A., serves as a Venture Partner at Arch Venture Partners, L.P. Mr. Leonard serves as the Executive Chairman and Chief Executive Officer of Unity Biotechnology, Inc. and ...


CEO Compensation Analysis

Compensation vs Market: Keith's total compensation ($USD2.73M) is above average for companies of similar size in the US market ($USD1.69M).

Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.9yrs

Average Tenure

51yo

Average Age

Experienced Management: UBX's management team is considered experienced (3.9 years average tenure).


Board Age and Tenure

4.3yrs

Average Tenure

52yo

Average Age

Experienced Board: UBX's board of directors are considered experienced (4.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 127.3%.


Management Team

  • Ned David (51yo)

    Co-Founder

    • Tenure: 8.1yrs
    • Compensation: US$2.86m
  • Keith Leonard (57yo)

    Executive Chairman & CEO

    • Tenure: 3.2yrs
    • Compensation: US$2.73m
  • Tammy Tompkins (54yo)

    General Counsel & Corporate Secretary

    • Tenure: 2.5yrs
  • Judy Campisi

    • Tenure: 8.9yrs
  • Dan Marquess (50yo)

    Chief Scientific Officer

    • Tenure: 4yrs
  • Bob Goeltz (46yo)

    Chief Financial Officer

    • Tenure: 2.3yrs
    • Compensation: US$1.29m
  • Jamie Dananberg (61yo)

    Chief Medical Officer

    • Tenure: 3.9yrs
    • Compensation: US$951.85k
  • Jan van Deursen

    • Tenure: 8.9yrs
  • Daohong Zhou

    • Tenure: 8.9yrs
  • Douglas Rich (50yo)

    Senior Vice President of Operations

    • Tenure: 2.7yrs

Board Members

  • Bob Nelsen (57yo)

    Independent Director

    • Tenure: 8.1yrs
  • Ned David (51yo)

    Co-Founder

    • Tenure: 8.1yrs
    • Compensation: US$2.86m
  • Cami Samuels (48yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$551.11k
  • Paul Berns (52yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$933.01k
  • Keith Leonard (57yo)

    Executive Chairman & CEO

    • Tenure: 3.2yrs
    • Compensation: US$2.73m
  • Kristina Burow (46yo)

    Independent Director

    • Tenure: 8.1yrs
    • Compensation: US$551.83k
  • Graham Cooper (49yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$167.90k
  • David Lacey (67yo)

    Independent Director

    • Tenure: 1.8yrs
    • Compensation: US$285.51k
  • Margo Roberts (64yo)

    Independent Director

    • Tenure: 1yrs
    • Compensation: US$533.51k

Company Information

Unity Biotechnology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Unity Biotechnology, Inc.
  • Ticker: UBX
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$384.073m
  • Shares outstanding: 45.94m
  • Website: https://www.unitybiotechnology.com

Number of Employees


Location

  • Unity Biotechnology, Inc.
  • 3280 Bayshore Boulevard
  • Suite 100
  • Brisbane
  • California
  • 94005
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UBXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2018
9U9DB (Deutsche Boerse AG)YesCommon StockDEEURMay 2018
0YC0LSE (London Stock Exchange)YesCommon StockGBUSDMay 2018

Biography

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company’s lead drug candidates include UBX0101 that is in Phase  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/14 01:58
End of Day Share Price2019/12/13 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.